Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Raises 30 Million Euro in Series C

NEW YORK, March 18 - Cellzome has raised 30 million euro ($31.9 million) in a Series C financing, the company said today.


The Heidelberg, Germanyproteomics company will use the funds for R&D  and proof-of-concept studies for its drug discovery process, which involves matching proteins to disease pathways and existing medicinal chemistry.


Invesco Private Capital led the financing round, and was joined by new investors Biofrontier Partners, SG Asset Management, and Yamanouchi Venture Capital; and prior investors Advent International, Atlas Venture, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences, Sofinnova Partners, and Stelios Papadopoulos.



The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.